Abstract 219P
Background
TNBC is an aggressive disease. AntiPD-1 and antiPD-L1 agents have shown promising results. TILs are prognostic factor while AR is controversial. We assessed the relationship among them and PDL1.
Methods
50 stage I-III TNBC patients diagnosed between 2008-2013 were analyzed. Minimum follow-up was 82 months or until death. AR, CD20, CD4 and CD8 were assessed by immunohistochemistry (IHQ). AR was positive if expression >=1%. Lymphocytes were evaluated as recommended by the international consensus of experts. Lymphocytes were high (HiL) or low (LoL) whether they were >=80% or <80%. PDL1 was analyzed by IHQ using Ventana antibody SP142. It was considered positive if expression was >=1%.
Results
AR+ was related to younger patients (p=0.009); CD8+ (p=0.002); PDL1<1% (p=0.007); Ki67<20% (p=0.019); N+ (p=0.015); CD8>CD4 (p=0.02). PDL1>=1% was related to Ki67>20% (p=0.025); grade III (p=0.037); CD20+(p=0.044). HiL was related to PDL1>=1% (p=0.02); grade III (p=0.009), CD20+ (p=0.04). And inversely related to CD8+ (p=0.02). Mean overall survival (OS) 108.48 months; N- median 121.75 months v N+ 92.83, p=0.061. PDL1 HR 0.69 (CI95% 0.25-1.90 p=0.69), CD20 HR 0.64 CI95% 0.18-2.26 p=0.4) and HiL HR 0.65 (CI95% 0.21-2.01p=0.45) trended to better OS but not reached statistical significance. Table: 219P
Shows patient and tumor features
| Patient | Tumor | ||||
| Age | 61.7 years Range (34-88) | T | T1-T2 | 44 (88%) | |
| T3-T4 | 6 (12%) | ||||
| Menopausal status | Premenopausal | 16 (32%) | Nodes (N) | Negative | 26 (52%) |
| Postmenopausal | 34 (68%) | Positive | 24 (48%) | ||
| Chemotherapy | Yes | 45 (90%) | Stage | I-II | 40 (80%) |
| No | 5 (10%) | III | 10 (20%) | ||
| Relapse | Yes | 14 (28%) | Grade (n 46) | I-II | 15 (32.6%) |
| No | 36 (72%) | III | 31 (67.4%) | ||
| Exitus | Yes | 17 (34%) | Ki67 (n 49) | <20% | 14 (28.6%) |
| No | 33 (66%) | >= 20% | 35 (71.4%) | ||
| AR | Yes | 13 (26%) | |||
| No | 37 (74%) | ||||
| Lymphocytes | |||||
| CD4 | 44.6% +/- 21.54 | T-lymphocytes | LoL | 35 (70%) | |
| HiL | 15 (30%) | ||||
| CD8 | 35.5% +/- 15.85 | CD4/CD8 | CD4>CD8 | 32 (64%) | |
CD4| 13 (26%) | | ||||
| CD4=CD8 | 5 (10.4%) | ||||
| CD20 | 12.3% +/- 10.56 | PDL1 (n 46) | <1% | 27 (58.7%) | |
| >=1% | 19 (41.3%) |
Conclusions
PDL1>=1% relates to grade III, high ki67, CD20+ and trends to better OS. This might mean that greater aggressiveness triggers a greater immune response. AR+ relates to PDL1<1% and Ki67<20% which might show they are poorly immunogenic.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.